- Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
- Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
- Geron to Participate in the B. Riley Securities Virtual Oncology Conference
More ▼
Key statistics
On Monday, Geron Corp (GERN:NSQ) closed at 3.18, -14.99% below its 52-week high of 3.74, set on Jun 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.35 |
---|---|
High | 3.38 |
Low | 3.00 |
Bid | 3.08 |
Offer | 3.09 |
Previous close | 3.36 |
Average volume | 30.61m |
---|---|
Shares outstanding | 546.06m |
Free float | 542.40m |
P/E (TTM) | -- |
Market cap | 1.83bn USD |
EPS (TTM) | -0.3246 USD |
Data delayed at least 15 minutes, as of Mar 18 2024 20:00 BST.
More ▼